Clinical trial NCT01484041: Dovitinib Plus an Aromatase Inhibitor for Metastatic Breast Cancer
Official title: A Phase I/II Trial of TKI258 (Dovitinib) in Combination With an Aromatase Inhibitor in Patients With Metastatic Breast Cancer
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE1
PHASE2
Conditions: Breast Cancer
Keywords: Breast cancer
postmenopausal
Lead sponsor: Georgetown University
Sponsor class: OTHER
Collaborators: name: Novartis Pharmaceuticals
First posted: 2011-12-02
Enrollment: 12
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This study is for women with confirmed hormone receptor positive HER-2 negative advanced breast cancer with evidence of disease resistance to an aromatase inhibitor.

The purpose of this study is to determine how well these medications work together and/or if they have any side effects in patients with hormone-receptor positive metastatic breast cancer who have demonstrated progression of disease after first line hormonal therapy.

This research is being done to determine if taking an already approved medicine (aromatase inhibitor) in combination with a new medication (dovitinib) results in better outcomes for patients with this disease.

Both dovitinib and an aromatase inhibitor are pills that will be taken at home.

Detailed description: This is a Phase I/Phase II open-label single arm trial of dovitinib in combination with anastrozole 1 mg daily, exemestane 25 mg daily, or letrozole 2.5 mg daily. Study subjects will receive the aromatase inhibitor on which they had previously derived clinical benefit.

Eligibility criteria: Inclusion Criteria:

* Female patients with breast cancer either in the primary or metastatic setting
* Tumor must be estrogen receptor and/or progesterone receptor positive and Her-2 negative
* Evidence of disease resistance to an aromatase inhibitor
* ECOG performance status 0 or 1
* Age 18 years or older
* Adequate laboratory values
* Able to give written informed consent
* Measurable disease
* No more than 2 prior chemotherapy regimens in the metastatic setting
* Unlimited prior hormonal therapy in the metastatic setting
* Life expectancy of greater than 3 months
* Post-menopausal
* Tumor must be available for central testing for FGFR1 amplification by FISH/CISH

Exclusion Criteria:

* Brain metastases
* Another primary malignancy within 3 years prior to starting drug therapy with the exception of adequately treated in-site carcinoma of the uterine cervix or skin cancer
* Chemotherapy within 3 weeks prior to starting study drug or not recovered from side effects of previous therapy
* Administration of nitrosurea or mitomycin-C within 6 weeks prior to starting study drug or not recovered from side effects of such therapy
* Administration of biologic therapy within 6 weeks prior to starting study drug or not recovered from side effects of such therapy
* Radiotherapy within 4 weeks prior to starting study drug or 2 weeks in the case of localized radiotherapy or not recovered from radiotherapy toxicities
* major surgery, open biopsy or significant traumatic injury within 4 weeks prior to starting study drug or a minor procedure, percutaneous biopsy or placement of a vascular access device within 1 week prior to starting study drug or not recovered from side effects of such procedure or injury
* Chronic concomitant bisphosphonate therapy for the prevention of bone metastases. Bisphosphonate/ denosumab therapy for the management of bone metastases or for the treatment of osteoporosis s allowed.
* Impaired cardiac function or clinically significant cardiac disease
* Impairment of GI function or GI disease that may significantly alter the absorption of dovitinib
* Cirrhosis, chronic active hepatitis, or chronic persistent hepatitis
* Known diagnosis of HIV infection
* Anticoagulation treatment with therapeutic doses of warfarin
* Any concurrent severe and/or uncontrolled concomitant medical condition that could cause unacceptable safety risks or compromise compliance with the protocol
* Pregnant or breast-feeding
* Unwilling or unable to comply with the protocol

Primary outcomes:
measure: Clinical Benefit Rate
timeFrame: 24 weeks
Secondary outcomes:
measure: Recommended Phase 2 Dose
timeFrame: 4 weeks
measure: Number of Participants With Adverse Events
timeFrame: 24 weeks
measure: Pharmacodynamic Effects
timeFrame: 24 weeks
measure: Progression-free Survival
timeFrame: 24 weeks
Other outcomes:
Locations:
city: Washington
country: United States
facility: Georgetown Lombardi Comprehensive Cancer Center
state: District of Columbia
Study officials:
affiliation: Georgetown University
name: Claudine Isaacs, MD
role: PRINCIPAL_INVESTIGATOR
References: